Treatment of murine fusariosis with SCH 56592

被引：54

作者：

Lozano-Chiu, M

Arikan, S

Paetznick, VL

Anaissie, EJ

Loebenberg, D

Rex, JH

机构：

[1] Univ Texas, Sch Med, Ctr Study Emerging & Reemerging Pathogens, Dept Internal Med,Div Infect Dis, Houston, TX 77030 USA

[2] Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA

[3] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1999年 / 43卷 / 03期

关键词：

D O I：

10.1128/AAC.43.3.589

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Doses of 10 to 100 mg of the azole antifungal agent SCH 56592/kg of body weight/day were studied in immunocompetent mice as therapy for systemic infection by Fusarium solani. Treatment was begun 1 h after intravenous infection and continued daily for 4 or 13 doses. Prolongation of survival and organ clearance were dependent on both the dose and the duration of SCH 56592 therapy, with the best results seen at 50 and 100 mg/kg/day. The results at the highest doses of SCH 56592 used (50 or 100 mg/kg/day) were comparable to those obtained with amphotericin B at 1 mg/kglday. SCH 56592 has potential for therapy of systemic infections caused by F. solani.

引用

页码：589 / 591

页数：3

共 25 条

[1] THE EMERGING ROLE OF FUSARIUM INFECTIONS IN PATIENTS WITH CANCER [J].

ANAISSIE, E ;

KANTARJIAN, H ;

RO, J ;

HOPFER, R ;

ROLSTON, K ;

FAINSTEIN, V ;

BODEY, G .

MEDICINE, 1988, 67 (02) :77-83

[2]

ANAISSIE EJ, 1990, NEW YORK STATE J MED, V90, P586

[3]

ANAISSIE EJ, 1992, J INFECT DIS, V165, P1155, DOI 10.1093/infdis/165.6.1155

[4]

ATTAPATTU MC, 1986, J MED VET MYCOL, V24, P105

[5]

COLLINS MS, 1977, SABOURAUDIA, V15, P151

[6] COMPARATIVE AND COLLABORATIVE EVALUATION OF STANDARDIZATION OF ANTIFUNGAL SUSCEPTIBILITY TESTING FOR FILAMENTOUS FUNGI [J].

ESPINELINGROFF, A ;

DAWSON, K ;

PFALLER, M ;

ANAISSIE, E ;

BRESLIN, B ;

DIXON, D ;

FOTHERGILL, A ;

PAETZNICK, V ;

PETER, J ;

RINALDI, M ;

WALSH, T .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (02) :314-319

[7]

FISHER NL, 1982, PHYTOPATHOLOGY, V72, P151, DOI 10.1094/Phyto-72-151

[8] OPPORTUNISTIC FUSARIAL INFECTIONS IN HUMANS [J].

GUARRO, J ;

GENE, J .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1995, 14 (09) :741-754

[9] Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. [J].

Law, D ;

Moore, CB ;

Denning, DW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2310-2311

[10]

LOZANO M, 1990, ENFERM INFEC MICR CL, V8, P78

← 1 2 3 →